APA (7th ed.) Citation

MS, S., KE, M., ML, E., S, J., K, B., J, V. V., . . . A, M. (2025). The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. The Lancet. Infectious diseases, 25(3), e122. https://doi.org/10.1016/S1473-3099(25)00007-6

Chicago Style (17th ed.) Citation

MS, Suthar, et al. "The KP.2-adapted COVID-19 Vaccine Improves Neutralising Activity Against the XEC Variant." The Lancet. Infectious Diseases 25, no. 3 (2025): e122. https://doi.org/10.1016/S1473-3099(25)00007-6.

MLA (9th ed.) Citation

MS, Suthar, et al. "The KP.2-adapted COVID-19 Vaccine Improves Neutralising Activity Against the XEC Variant." The Lancet. Infectious Diseases, vol. 25, no. 3, 2025, p. e122, https://doi.org/10.1016/S1473-3099(25)00007-6.